Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse(University of Wisconsin–Madison), Niroo Gupta(Teleflex (United States))
Cited by 1,291
Related Papers
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
|Journal of Allergy and Clinical Immunology|2007|933
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
|New England Journal of Medicine|2011|870
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
|Annals of Internal Medicine|2011|550
Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial
|The Lancet|2008|456
Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription.
|Journal of Clinical Investigation|1997|336